Cardio Diagnostics Holdings, Inc. (CDIO)
NCM · Healthcare · Biotechnology
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About Cardio Diagnostics Holdings, Inc.
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management. It also provides CardioInnovate360, a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases; and HeartRisk, a SaaS cardiovascular disease risk intelligence platform. It serves telemedicine providers; provider organizations, such as concierge practices, longevity clinics, and risk-bearing provider organizations; and employer organizations. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 3K | 4K | 3K | 5K |
| Operating Income | (1.7M) | (1.5M) | (1.8M) | (1.5M) |
| Net Income | (1.7M) | (1.5M) | (1.8M) | (1.5M) |
| Diluted EPS | $-0.98 | N/A | $-0.63 | $-0.51 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 950.00 | 17K | 35K | 15K |
| Operating Income | (4.5M) | (7.2M) | (8.4M) | (6.5M) |
| Net Income | (4.7M) | (8.4M) | (8.4M) | (6.5M) |
| Diluted EPS | $-45.30 | $-19.80 | $-9.35 | $-3.71 |